ShareValue scores for DMAA: Valuation 40, Quality 50, Growth 60, Health 40.
DMAANASDAQ
Drugs Made In America Acquisition Corp. Ordinary Shares
$10.71
(0.00%)
DMAANASDAQ
Drugs Made In America Acquisition Corp. Ordinary Shares
$10.71(0.00%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
6% to 16%
Rating
Trap Risk
Return
6% to 16%
Valuation
40
Fair Value
Price vs Value
Quality
50
Moderate
Business Strength
Growth
60
Moderate
Revenue & Earnings
Health
40
Moderate
Financial Stability
Momentum
53
Neutral
Price Trend
Company Details
About
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Market Cap$260M
P/E Ratio53.3
Dividend YieldNone
Sector Rank#2075
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026